当前位置: 首页 > 期刊 > 《中国现代医生》 > 202022
编号:13820324
他莫昔芬对绝经后乳腺癌术后患者子宫内膜的影响及宫腔镜的诊断价值(4)
http://www.100md.com 2020年8月5日 《中国现代医生》 202022
     [10] Hann LE,Giess CS,Bach AM,et al. Endometrial thickness in tamoxifen-treated patients:correlation with clinical and pathologic findings[J]. AJR Am J Roentgenol,1997, 168:657-661.

    [11] Markovitch O,Tepper R,Fishman A,et al. Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy[J]. Maturitas,2008,59: 387-393.

    [12] Timmerman D,Deprest J,Bourne T,et al. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen[J]. Am J Obstet Gynecol,1998,179: 62-70.

    [13] Gu R,Jia W,Zeng Y,et al. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients:A retrospective cohort study[J].BMC Cancer,2012,12:161.

    [14] Ramondetta LM,Sherwood JB,Dunton CJ,et al. Endometrial cancer in polyps associated with tamoxifen use[J]. Am J Obstet Gynecol,1999,180: 340-341.

    [15] Jeon SJ,Lee JI,Lee M,et al. Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen[J]. Obstet Gynecol Sci,2017,60:26-31.

    (收稿日期:2019-06-26), 百拇医药(朱一迪)
上一页1 2 3 4